Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimegepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 0.93 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimegepant SCHEMBL29413909 | 1.00 | CALCRL (0.93) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL30563158 | 0.99 | CALCRL (0.94) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL29592766 | 0.96 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL29374210 | 0.96 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL1670839 | 0.96 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL24131009 | 0.96 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL2523699 | 0.96 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL1670580 | 0.96 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| SCHEMBL30721761 | 0.94 | CALCRL (0.94) | CALCRLADRB2CYP3A4 | |
| SCHEMBL30721794 | 0.92 | CALCRL (0.92) | CALCRLADRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108049-A1 | ORAL FAST-DISPERSING DOSAGE FORM OF RIMEGEPANT | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-06 | — | — | US | disclosed |
| EP-4110337-A1 | ORAL FAST-DISPERSING DOSAGE FORM OF RIMEGEPANT | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022251752-A2 | DUAL TREATMENT OF MIGRAINE | BIOHAVEN PHARMACEUTICAL IRELAND DAC (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-115335051-A | Oral fast-dispersing dosage form of rimaidiazepam | 拜尔哈文制药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108049-A1 | ORAL FAST-DISPERSING DOSAGE FORM OF RIMEGEPANT | OPRD1, DRD1, HTR1A | CALCRL 778/4885ADRB2 473/4885CYP3A4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.